Senti Biosciences Holdings, Inc. (SNTI) Form 8-K — Jul 15, 2026
Senti Biosciences entered into a definitive agreement to sell substantially all of its existing business and pipeline to an affiliate of its largest stockholder, Celadon Partners. In exchange for the merger, public stockholders will receive Contingent Value Rights (CVRs) representing the right to receive up to $60 million in cash if specific regulatory and sales milestones for SENTI-202 are achieved. Following the transaction, the company is expected to remain publicly listed but with a significantly streamlined operating structure focused solely on early-stage programs such as its Regulator Dial technology.
Key figures
- Cash Position
- 6500000
- Termination fee
- 2500000
- Shares outstanding
- 31144754
- Cvr sales milestone
- 30000000
- Total cvr potential
- 60000000
- Cvr bla filing milestone
- 10000000
- Additional funding amount
- 6000000
- Cvr fda approval milestone
- 20000000
- Shares outstanding options
- 4771482
Price after filing
Close on the filing date to close N calendar days later (from $0.58). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.